Nutrition
Volume 26, Issue 7 , Pages 779-783 , July 2010

Impact of probiotic supplementation on mortality of induced 1,2-dimethylhydrazine carcinogenesis in a mouse model

Received 15 July 2009 ,Accepted 9 January 2010.

References 

  1. FAO/WHO Expert Consultation. “Guidelines for the Evaluation of Probiotics in Food.”. London: Ontario (Canada); 2002;
  2. Donohue DC, Salminen S. Safety of probiotic bacteria. Asia Pacific J Clin Nutr. 1996;5:25–28
  3. Bengmark S, Gianotti L. Nutritional support to prevent and treat multiple organ failure. World J Surg. 1996;20:474–481
  4. Shortt C. The probiotic century: historical and current perspectives. Trends Food Sci Technol. 1999;10:411–417
  5. Martins FS, Rodrigues ACP, Tiago FCP, Penna FJ, Rosa CA, Arantes RME, et al. Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice. J Med Microbiol. 2007;56:352–359
  6. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr. 2001;73(suppl):465S–470S
  7. Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L rhamnosus strain GG. Clin Infect Dis. 1999;28:1159–1160
  8. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115:178–181
  9. Viggiano M, Badetti C, Bernini V, Garabedian M, Manelli JC. Saccharomyces boulardii fungemia in a patient with severe burns. Ann Fr Anesth Reanim. 1995;14:356–358
  10. Rijnders BJ, Van WE, Verwaest C, Peetermans WE. Saccharomyces fungemia complicating Saccharomyces boulardii treatment in a non-immunocompromised host. Intensive Care Med. 2000;26:825
  11. Lherm T, Monet C, Nougiere B, Soulier M, Larbi D, Gall CL, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med. 2002;28:797–801
  12. Riquelme AJ, Calvo MA, Guzman AM, Depix MS, García P, Pérez C, et al. Saccharomyces cerevisiae Fungemia after Saccharomyces boulardii treatment in immunocompromisedpatients. J Clin Gastroenterol. 2003;36:41–43
  13. Cassone M, Serra P, Mondello F, Girolamo A, Scafetti S, Pistella E, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41:5340–5343
  14. Lestin F, Pertschy A, Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr. 2003;128:2531–2533
  15. Boyle RB, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr. 2006;83:1256–1264
  16. Surawicz CM. Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhea in humans. Best Pract Res Clin Gastroenterol. 2003;17:775–783
  17. Born P, Lersch C, Zimmerhackl B, Claassen M. The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr. 1993;118:765
  18. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997;23:517–523
  19. Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy. 1995;41:48–81
  20. Marteau PR. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430–436
  21. Reid G. Probiotic agents to protect the urogenital tract against infection. American J Clin Nutr. 2001;73:437–443
  22. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462–1464
  23. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697–698
  24. Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale?. Inflamm Bowel Dis. 2000;6:107–115
  25. Shanahan F. Probiotics and inflammatory bowel disease: from fads to fantasy to acts and future. Br.. J. Nutr. 2000;88:5–9
  26. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Disc Today. 2003;8:692–700
  27. Cummings JH, Macfarlane GT, Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol. 2003;4:9–20
  28. Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J. 2006;82:376–382
  29. Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir U. Probiotics—compensation for lactase insufficiency. Am J Clin Nutr. 2001;73:421–429
  30. Gilliland SE, Walker DK. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci. 1990;73:905–911
  31. Taranto MP, Medici M, Perdigon G, Holgado APR, Valdez GF. Evidence for hypocholesterolemic effect of Lactobacillus reuteri in hypercholesterolemic mice. J Dairy Sci. 1998;81:2336–2340
  32. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999;5:290–292
  33. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38:457–458
  34. DeGroote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005;24:278–280
  35. Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol. 1998;36:325–326
  36. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med. 1998;105:71–72
  37. Corrêa NB, Peret Filho LA, Penna FJ, Lima FM, Nicoli JR. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005;39:385–389
  38. Surawicz CM. Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhea in humans. Best Pract Res Clin Gastroenterol. 2003;17:775–783
  39. Elmer GW, Mcfarland LV. Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am. 2001;30:837–854
  40. Born P, Lersch C, Zimmerhackl B, Claassen M. The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr. 1993;118:765
  41. Bleichner G, Blehaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997;23:517–523
  42. Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy. 1995;41:48–58
  43. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979;23:403–411
  44. Berg RD. Translocation of microbes from the intestinal tract. In:  Tannock GW editors. Medical importance of the normal microflora. London: Kluwer Academic Publishers; 1999;p. 338–370
  45. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4:430–435
  46. Morehouse JL, Specian RD, Stewart JJ, Berg RD. Translocation of indigenous bacteria from the gastrointestinal tract of mice after oral ricinoleic acid treatment. Gastroenterology. 1986;91:673–682
  47. Berg RD, Wommack E, Deitch EA. Immunosuppression and intestinal bacterial overgrowth synergistically promote bacterial translocation. Arch Surg. 1988;123:1359–1364
  48. Mannick JA, Rodrick ML, Lederer JA. The immunologic response to injury. J Am Coll Surg. 2001;193:237–244
  49. Broaddus RR, Wargovich MJ, Castro GA. Early stages of 1,2-dimethylhydrazine-induced colon carcinogenesis suppress immune-regulated ion transport of mouse distal colon. Cancer Res. 1994;54:5930–5936
  50. Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis. 1999;20:1425–1431
  51. Berg RD. Bacterial translocation from the intestines. Exp Anim. 1985;34:1–16
  52. Van Leeuwen PAM, Boermeester MA, Houdijk APJ. Ferwerda ChC, Cuesta MA, Meyer S. Clinical significance of translocation. Gut. 1994;35:28–34
  53. Alexander JW, Boyce ST, Babcock GF, Gianotti L, Peck MD, Dunn DL, et al. The process of microbial translocation. Ann Surg. 1990;212:496–510
  54. Mattar AF, Drongowski RA, Coran AG, Harmon CM. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int. 2001;17:265–268
  55. Eizaguirre I, Garcia Urkia N, Asensio AB, Zubillaga I, Zubillaga P, Vidales C, et al. Probiotic supplementation reduces the risk of bacterial translocation in experimental short bowel syndrome. J Pediatr Surg. 2002;37:699–702
  56. Berg R, Bernasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis. 1993;168:1314–1318
  57. Gianotti L, Alexander JW, Pyles T, Fukushima RM. Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance. The role of nitric oxide. Ann Surg. 1993;217:644–654

PII: S0899-9007(10)00034-1

doi: 10.1016/j.nut.2010.01.008

Nutrition
Volume 26, Issue 7 , Pages 779-783 , July 2010

Article Tools

* Image Usage & Resolution